Evolus (NASDAQ:EOLS) Announces Earnings Results, Misses Expectations By $0.09 EPS

Evolus (NASDAQ:EOLS) released its quarterly earnings data on Tuesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.09), Zacks reports. Evolus had a negative net margin of 22.33% and a negative return on equity of 847.60%.

Evolus Trading Up 0.1 %

Shares of EOLS stock traded up $0.01 on Tuesday, reaching $14.35. 899,628 shares of the company’s stock were exchanged, compared to its average volume of 593,467. The company’s fifty day simple moving average is $12.72 and its 200 day simple moving average is $14.08. The stock has a market capitalization of $908.66 million, a PE ratio of -15.77 and a beta of 1.33. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus has a 52 week low of $9.25 and a 52 week high of $17.82.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Barclays boosted their price objective on Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Tuesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Friday, February 14th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.